New cisplatin analogues in development. A review - PubMed (original) (raw)
Review
New cisplatin analogues in development. A review
Raymond B Weiss et al. Drugs. 1993 Sep.
Erratum in
- Drugs. 1993 Sep;46(3):377
Abstract
Cisplatin was discovered to have cytotoxic properties in the 1960s, and by the end of the 1970s it had earned a place as the key ingredient in the systemic treatment of germ cell cancers. Since the early seminal work in the preclinical and clinical development of this drug, several thousand analogues have been synthesised and tested for properties that would enhance the therapeutic index of cisplatin. About 13 of these analogues have been evaluated in clinical trials, but only one (carboplatin) has provided definite advantage over cisplatin and achieved worldwide approval. However, carboplatin has afforded benefit only in reducing some cisplatin toxicities; it has not enlarged the spectrum of platinum-sensitive cancers, nor has it proved active in cisplatin-resistant cancers. The major obstacle to the efficacy of cisplatin or carboplatin is platinum resistance, either innate or acquired. The mechanisms of this resistance have been under intense study, and many of the cisplatin analogues synthesised in the past decade have been designed specifically with the hope of overcoming platinum resistance. The mechanism of the cytotoxic activity of platinum complexes has also been studied intensely. Recently synthesised analogues have been designed to interact with DNA in a manner different from cisplatin and carboplatin, with the desire of finding new structures with a superior or wider spectrum of antitumor efficacy. Most recently, water soluble platinum complexes that retain antitumour activity, but that can be effectively absorbed after oral administration, have been synthesised with the goal of improving patient quality of life. Nine platinum analogues are currently in clinical trials around the world (ormaplatin [tetraplatin], oxaliplatin, DWA2114R, enloplatin, lobaplatin, CI-973 [NK-121], 254-S, JM-216 and liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) [LNDDP]). Some of these analogues only represent attempts to reduce cisplatin toxicity and/or allow administration without forced hydration and diuresis, which carboplatin already does. Others are 'third generation' complexes shown to have limited or no cross-resistance with cisplatin in preclinical studies. They are being tested clinically with particular attention to this highly desirable property.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
- Comparative adverse effect profiles of platinum drugs.
McKeage MJ. McKeage MJ. Drug Saf. 1995 Oct;13(4):228-44. doi: 10.2165/00002018-199513040-00003. Drug Saf. 1995. PMID: 8573296 Review. - Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues.
Hydes PC, Russell MJ. Hydes PC, et al. Cancer Metastasis Rev. 1988 Apr;7(1):67-89. doi: 10.1007/BF00048279. Cancer Metastasis Rev. 1988. PMID: 3293834 Review. - Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR. Kelland LR, et al. Cancer Res. 1993 Jun 1;53(11):2581-6. Cancer Res. 1993. PMID: 8388318 - New platinum antitumor complexes.
Kelland LR. Kelland LR. Crit Rev Oncol Hematol. 1993 Dec;15(3):191-219. doi: 10.1016/1040-8428(93)90042-3. Crit Rev Oncol Hematol. 1993. PMID: 8142057 Review. - Platinum coordination complexes which circumvent cisplatin resistance.
Harrap KR, Kelland LR, Jones M, Goddard PM, Orr RM, Morgan SE, Murrer BA, Abrams MJ, Giandomenico CM, Cobbleigh T. Harrap KR, et al. Adv Enzyme Regul. 1991;31:31-43. doi: 10.1016/0065-2571(91)90007-9. Adv Enzyme Regul. 1991. PMID: 1877393
Cited by
- Trimethyltin(IV) Bearing 3-(4-Methyl-2-oxoquinolin-1(2H)-yl)propanoate Causes Lipid Peroxidation-Mediated Autophagic Cell Death in Human Melanoma A375 Cells.
Kasalović MP, Dimić D, Jelača S, Maksimović-Ivanić D, Mijatović S, Zmejkovski BB, Schreiner SHF, Rüffer T, Pantelić NĐ, Kaluđerović GN. Kasalović MP, et al. Pharmaceuticals (Basel). 2024 Mar 14;17(3):372. doi: 10.3390/ph17030372. Pharmaceuticals (Basel). 2024. PMID: 38543158 Free PMC article. - Engineered biomaterial delivery strategies are used to reduce cardiotoxicity in osteosarcoma.
Hou Y, Wang J, Wang J. Hou Y, et al. Front Pharmacol. 2023 Oct 3;14:1284406. doi: 10.3389/fphar.2023.1284406. eCollection 2023. Front Pharmacol. 2023. PMID: 37854721 Free PMC article. Review. - Oxidation of the Platinum(II) Anticancer Agent [Pt{(_p_-BrC6F4)NCH2CH2NEt2}Cl(py)] to Platinum(IV) Complexes by Hydrogen Peroxide.
Ojha R, Junk PC, Bond AM, Deacon GB. Ojha R, et al. Molecules. 2023 Sep 1;28(17):6402. doi: 10.3390/molecules28176402. Molecules. 2023. PMID: 37687231 Free PMC article. - Cisplatin for cancer therapy and overcoming chemoresistance.
Ranasinghe R, Mathai ML, Zulli A. Ranasinghe R, et al. Heliyon. 2022 Sep 14;8(9):e10608. doi: 10.1016/j.heliyon.2022.e10608. eCollection 2022 Sep. Heliyon. 2022. PMID: 36158077 Free PMC article. Review. - Methanolic Phoenix dactylifera L. Extract Ameliorates Cisplatin-Induced Hepatic Injury in Male Rats.
Gad El-Hak HN, Mahmoud HS, Ahmed EA, Elnegris HM, Aldayel TS, Abdelrazek HMA, Soliman MTA, El-Menyawy MAI. Gad El-Hak HN, et al. Nutrients. 2022 Feb 28;14(5):1025. doi: 10.3390/nu14051025. Nutrients. 2022. PMID: 35268000 Free PMC article.
References
- Cancer Res. 1988 Aug 15;48(16):4509-12 - PubMed
- Br J Cancer. 1989 Nov;60(5):767-9 - PubMed
- Biomed Pharmacother. 1989;43(4):237-50 - PubMed
- Cancer Res. 1987 Jan 15;47(2):414-8 - PubMed
- Cancer Res. 1977 Sep;37(9):3455-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous